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Abstract
Echocardiography is comparatively inexpensive relative to other modern cardiovascular imaging
tools. It is widely available, even in poor countries, and provides a comprehensive evaluation of
cardiac structure and function. It is an ideal tool for the evaluation of patients with valvular heart
disease and provides important prognostic information. This review of recent literature highlights
reports on outcomes data and provides a clinically valuable summary in table format.
Introduction and context
The diagnostic criteria for echocardiographic assessment
of valvular heart disease are well established [1]. An ever-
growing preponderance of literature highlights the
usefulness of echocardiography as a prognostic indicator
for outcomes in valvular heart disease, particularly aortic
valve (AV) and mitral valve (MV) disorders. This review
focuses on recent published reports that are intended to
provide the physician with the necessary data to
transition from an anatomic report to a more prognostic
report in an effort to improve patient management
choices.
Recent advances
Aortic stenosis
A preoperative left ventricular (LV) end-systolic index of
less than 27.5 mm/m
2 as measured by echocardiography
has been shown to be a strong predictor of good
intermediate LV recovery following aortic valve replace-
ment (AVR) surgery for severe aortic stenosis (AS) [2].
Furthermore,priortoAVR,anextremelypoor(21%)2-year
event-free survival can be expected in asymptomatic
patients with mostly calcific AS and a peak gradient of
greater than 64 mm Hg (peak Doppler velocity >4.0 m/s)
[3]. This point emphasizes the critical role of serial
echocardiography and clinical evaluation of these patients.
In patients with a bicuspid AV, a peak gradient of at least
80mmHgandanaorticvalvearea(AVA)ofnotmorethan
0.75 cm
2 have been shown to predict the need for urgent
AV surgery [4].
In patients with AS and normal left ventricular ejection
fraction (LVEF), mitral annular tissue Doppler imaging
(TDI) correlates significantly with AVA and amino-
terminal pro-B-type natriuretic peptide (BNP) levels.
Mortality and the need for AVR are better predicted by a
reduced septal annular diastolic atrial velocity (A
0) of less
than 9.6 cm/s than with AVA or BNP [5]. In patients with
AS and reduced LV contractility, a critical understanding
of LV contractile reserve (CR) is required if the mean AV
gradient is low (<30 mm Hg). In these patients, low-dose
dobutamine infusion (up to 20 mg/kg per minute) allows
the differentiation between patients with true severe
(fixed) AS who will benefit from AVR from those with
either nonsevere (relative) AS or a late-stage (nonviable)
cardiomyopathy for whom AVR may be harmful. In a
multicenter prospective evaluation of patients with AS
(AVA of approximately 0.7 cm
2) and a low AV gradient
(mean of approximately 29 mm Hg), those with a 20%
increase in LV stroke volume during dobutamine
infusion had an operative mortality significantly lower
than those without (5% versus 32%) [6]. Furthermore, a
lack of CR or a very low mean gradient (<20 mm Hg) was
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ratios of 10.9 and 4.7, respectively.
Proper prosthesis selection is of crucial importance in
preventing prosthesis patient mismatch (PPM), an
independent predictor of mortality after AVR [7].
Recently, transcatheter AVR has become possible and
will certainly beadvanced in subsequent years. Outcomes
in these patients are variable, and the need for permanent
pacemaker insertion is not uncommon. Recently, this has
been predicted by two simple two-dimensional echo-
cardiography (2DE) features: severe septal hypertrophy
(>17 mm) and baseline thickness of the native non-
coronary cusp (>8 mm) as measured by transesophageal
echocardiography (TEE) [8].
Aortic regurgitation
In the setting of aortic regurgitation (AR), current
guidelines recommend surgery for asymptomatic
patients with a maximal left ventricular end-diastolic
diameter (LVDd) of greater than 55 mm or an LVEF of
less than 50% [9]. This stems from the knowledge that
outcomes worsen when these values are exceeded. Use of
an indexed LVDd of less than 25 mm/m
2 in patients with
a body surface area (BSA) of not more than the 25th
percentile (BSA of 1.43-1.68 m
2) is associated with a
drop in age-adjusted mortality and is also a better
prognostic indicator for unfavorable outcomes 1 year
after surgery as measured by an LVEF of less than 50%
[10]. Asymptomatic patients with severe quantitative AR
[an effective regurgitant orifice (ERO) of >35 mm
2,a
regurgitant volume of >60 mL, or a regurgitant fraction
percentage of >50%] and normal LVEF (>50%) have a
greater than fivefold increase in mortality. Furthermore,
cardiac events at 10 years were 90% with an end-systolic
volume index (ESVI) of greater than 45 mL/m
2 but only
40% with an ESVI of less than 45 mL/m
2 [11].
Mitral valve disease
Functionalmitralregurgitation(MR)duetoleftventricular
dysfunction is associated with a poor outcome when the
MR is quantified as more than mild (ERO >20 mm
2)a n d
the left ventricular end-systolic volume is increased at rest
(>95mL/m
2)orafterexercise(leftventricularend-diastolic
volume >120 mL/m
2) [11]. In patients with MV prolapse,
outcomescanbepredictedsimplyviatheserialprogression
of demonstrated MR, regardless of age, gender, prolapse
location, valve thickening, or pre-existing MR [12].
Increases in MR by greater than 1 MR grade are associated
with left atrial and ventricular dilatation and an overall
poor prognosis.
Flail leaflet plays a major role in the etiology of organic
MR. In addition, the presence of flail leaflet is a poor
prognostic indicator, with much of this patient popula-
tion dying or requiring surgery within 10 years of
receiving the diagnosis [13]. Early surgery, particularly
MV repair, in both the symptomatic and asymptomatic
patient population has been shown to reduce the rates of
cardiac events [14]. However, the recurrence of 2/4 grade
or worse MR in patients undergoing MV repair for flail
leaflet is between 2% and 4% per year [15]. The use of
real-time three-dimensional echocardiography (RT3DE)
permits direct analysis of mitral annular geometry and
precise quantitative analysis of leaflet geometry. This tool
holds great promise in improving our understanding of
flail leaflet in MR as well as enhancing the surgical
precision in techniques used for repair [15].
Patients may develop LV dysfunction (EF <50%) after
MV surgery. Large preoperative MR volumes (≥80 mL)
are strongly associated with unexpected postoperative LV
dysfunction and are useful in the timing of surgical
intervention in asymptomatic patients [16]. A mitral E/E
0
(early mitral filling velocity/early diastolic mitral annular
velocity) ratio of greater than 13.5 as determined by the
average septal and lateral mitral annular TDI velocities
predicts a twofold worse event-free survival, particularly
in patients with severe secondary MR due to heart failure
[17]. In patients with asymptomatic severe MR, an
end-systolic diameter of less than 45 mm, and an
ejection fraction (EF) of greater than 60%, peak systolic
tissue Doppler velocities at the lateral mitral annulus
accurately predicted postoperative reductions in EF
and therefore LV dysfunction. Specifically, a myocardial
systolic wave velocity of not more than 10 cm/s
appears to be predictive of a postoperative EF reduction
of at least 10% [18].
Of interest is the growing usefulness of RT3DE, which
permits full or partial volume image acquisition in
multiple planes [19]. Real-time assessment of mitral
annular geometry has enhanced our understanding of
the pathophysiology of MR [20]. In our opinion, in the
near future, most of the prognostic M-mode echocardio-
graphy and 2DE parameters previously reported will be
even more accurate at risk-stratifying patients by using
results of 3DE (owing to its superior reproducibility
and fewer restrictions on heart size and shape). This
technique is useful in quantifying mitral regurgitant
flows, usually underestimated with the proximal iso-
velocity surface area method using 2DE [21]. In fact,
while 2DE measurement of vena contracta width is a
commonly accepted method of assessing MR severity,
RT3DE permits more accurate assessment of this dimen-
sion. RT3DE measures nonspehrical regurgitant orifices
by direct planimetry without using calculations based on
inaccurate assumptions [22].
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Criteria Value Prognosis Reference
Aortic stenosis
Late diastolic annular velocity
(septal A
0)
<9.6 cm/s Predictor of cardiac mortality or need for aortic valve replacement
~50% at 1 year
[35]
Interventricular septal thickness >17 mm Specificity (100%) pacemaker implantation after transcatheter aortic valve
implantation
[7]
Noncoronary cusp thickness
(apical three-chamber view)
>8 mm Specificity (100%) pacemaker implantation after transcatheter aortic valve
implantation
[7]
LVESD index <27.5 mm/m
2 Sensitivity and specificity of 73% and 64% for predicting recovery of LV
function (LVEF improvement >10%) at 48 months after AVR
[2]
Peak gradient >64 mm Hg 79% 2-year event rate [3]
Peak velocity >4.0 m/s
Peak gradient
AVA
≥80 mm Hg
≤0.75 cm
2
Need for AVR in bicuspid AV, with 84% event-free survival at 1 year
after valve replacement
[4]
Prosthesis patient mismatch
Indexed EOA (aortic position) >0.85 cm
2/m
2 Mild PPM (not clinically significant) [29]
Indexed EOA (aortic position) ≤0.65 cm
2/m
2 Severe PPM (persistent high gradients, worse outcomes) [29]
Indexed EOA (mitral position) >1.2 cm
2/m
2 Mild PPM (not clinically significant) [29]
Indexed EOA (mitral position) ≤0.9 cm
2/m
2 Severe PPM (persistent high gradients, worse outcomes) [29]
Aortic regurgitation
Indexed LVDd ≥25 mm/m
2 88% chance of EF <50% 1 year after valve replacement, age-adjusted
expected EF <50% in 24.27% vs. 37.94% with ESD >50 mm
[8]
QASE severe AR RV ≥60 mL
RF >50%
ERO ≥30 mm
2
Cardiac events at 10 years: 63% vs. 34% (moderate AR) and 21%
(mild AR)
[10]
ESVI ≥45 mL/m
2 Cardiac events at 10 years: 87% vs. 40% [10]
Pulmonic regurgitation
PR RVESVi <150 mL/m
2 Increased cardiac event rate and persistent RV dilation in absence
or delay of PVR
[33]
Mitral stenosis
Updated MS score
(calcification)
No calcification = 0
Leaflet margins = 2
Leaflet bodies = 4
Commissures = 6
[36]
Updated MS score
(subvalvular involvement)
None = 0
<50% chord = 2
≥50% chord = 4
Entire chord = 6
[36]
Total summed updated MS score >4 Poor outcome: less success with PBMV [36]
Mitral regurgitation
Peak stress end-diastolic volume 120 mL/m
2 50% survival at 25-month follow-up vs. 88.9% (peak stress EDVI <120 mL/m
2) [11]
Resting end-systolic volume ≥95 mL/m
2 36% survival at 25-month follow-up vs. 92.6% (ESV <95 mL/m
2) [11]
Effective regurgitant orifice
(baseline)
≥20 mm
2 50% survival at 25-month follow-up vs. 92% ERO <20 mm
2 [11]
Mitral regurgitation volume ≥80 mL Unexpected postoperative LV dysfunction in 20% of patients [16]
E/E
0 ratio >13.5 Event-free survival 64% vs. 31% (E/E
0 ratio ≤13.5) in patients with MR [17]
MVP Increase ≥1 MR grade 60% MVP-related cardiac events at 6.2 ± 2.9 years vs. 26% of nonprogressors [12]
Sm velocity ≤10 cm/s Postoperative EF reduction ≥10% with 78% sensitivity, 95% specificity [18]
Indexed mitral EOA <1.2 cm
2/m
2 Associated with a postoperative PA systolic pressure >40 mm Hg [37]
Preoperative PAP ≥50 mm Hg 53% incidence of postoperative LV dysfunction [22]
A
0 0
velocity/earlydiastolicmitralannularvelocity;EDVI,end-diastolicvolumeindex;EF,ejectionfraction;EOA,effectiveorificearea;ERO,effectiveregurgitantorifice;ESD,
ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; MS, mitral stenosis; MVP, mitral valve prolapse; PA, pulmonary artery; PAP,
pulmonary valve replacement; QASE, quantitative American Society of Echocardiography; RF, regurgitant fraction; RV, right ventricle; RVESVi, right ventricular
end-systolic volume index; Sm, myocardial systolic wave velocity.
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, late(atrial) diastolicmitralannular velocity;AR, aorticregurgitation;AV,aortic valve; AVA,aortic valvearea;AVR, aortic valve replacement; E/E, early mitral filling
pulmonary artery systolic pressure; PBMV, percutaneous balloon mitral valvuloplasty; PPM, prosthesis patient mismatch; PR, pulmonic regurgitation; PVR,
end-systolic diameter; ESV, end-systolic volume; ESVI, end-systolic volume index; LV, left ventricle; LVDd, left ventricular diastolic dysfunction; LVEF, left ventricularAn important complication of MV disease [both MR and
mitral stenosis (MS)] is pulmonary hypertension (PH)
with subsequent right ventricular dysfunction and failure
[23]. A preoperative pulmonary artery systolic pressure
(PAP) of at least 50 mm Hg is an independent predictor
of postoperative LV dysfunction as compared with
patients with a PAP of not more than 30 mm Hg and a
similar preoperative LVEF. While current guidelines
indicate surgical intervention at a PAP of greater than
50 mm Hg, these findings may suggest the need for a
more aggressive surgical approach to patients with MR
and PH [23]. An important avoidable complication of
mitral valve replacement (MVR) is PPM, which is
strongly associated with PH after surgery. An indexed
mitral effective orifice area (EOA) of less than 1.2 cm
2/m
2
is associated with a postoperative PAP of greater
than 40 mm Hg [24]. With the onset of MS, left atrial
pressure increases. As severity of the disease progresses,
increases in PAP occur with subsequent RV dysfunction,
tricuspid annular dilation (TAD), and tricuspid regurgita-
tion (TR) [24]. Moderate to severe postoperative TR in
MVR is a strong predictor of all-cause mortality [25]. TR
also indicates poor prognosis in patients undergoing
balloon mitral valvotomy [24]. Reduction of PAP as a
result of MVR may not prevent persistent TAD post-
operatively. Right ventricular dysfunction, once sympto-
matic, may already be irreversible. Echocardiographic
assessment of the tricuspid valve is therefore a necessary
diagnostic component in patients with MS. A 2DE
finding of a TAD of greater than 3.5 cm (regardless of
severity of TR) indicates the consideration for tricuspid
annuloplasty to be performed concomitantly with MV
surgery [24].
Pulmonic regurgitation
One important right-sided valve lesion to mention, as its
incidence is increasing, is pulmonic regurgitation (PR)
[26]. There are now more adults living in the US with
congenital heart disease than children and most of the
former arrive there via successful pediatric surgical
interventions. Progressive PR is common in these
adolescents and adults. Initially, the RV responds well,
but variably, to severe PR. However, at some point, the
RV will fail. This ‘point of no return’ seems to be an RV
ESVI of greater than 150 mL/m
2 [23].
Implications for clinical practice
This review confirms the importance of quantifiable
information gathered via M-mode, 2D, 3D, and Doppler
echocardiography in predicting patient outcomes. The
updated parameters are easily obtained and are more
accurate at risk-stratifying patients than previously used
qualitative values [27]. These measurements are crucial
for determining prognosis and utilization of surgical and
percutaneous interventions in patients with valvular
heart disease.
In the setting of AS, prognostic parameters that integrate
the valvular, ventricular, and vascular components of the
disease may allow more optimal timing of intervention
[28]. The fact that the tissue Doppler echocardiography A
0
is a better predictor of mortality than AVA is consistent
with the acknowledged importance of compensatory left
atrial function in the natural history of AS [5]. Aortic, and
to a lesser extent mitral, PPM may be avoided by
calculating the projected indexed EOA of the considered
prosthesis prior to intervention. The indexed EOA is
calculated by dividing the EOA of the prosthesis by the
patient’s BSA and may be used to select prostheses as well
as to quantify the severity of PPM according to the
guidelines in Table 1 [29]. For patients with AR, a number
of prognostic echo values that should be considered as
criteria for valve surgery are provided [8].
One of the major reasons echocardiography is such a
frequently employed diagnostic tool is that it allows serial
exams to be performed safely. By knowing the quantitative
dimensionsthatprovidepertinentprognosticinformation,
the physician may choose to alter the interval for
subsequent evaluation. For example, an asymptomatic
patient normally followed annually with moderate to
severe AR and a recently determined LV diastolic index of
24 mm/m
2 would warrant very close follow-up (as well as
quantitationofARseverity).This patient, on the edgeofLV
failure, should probably not wait another year prior to
evaluation.Onthecontrary,iftheLVDdisonly18mm/m
2,
then waiting a year remains reasonable. Furthermore,
increases in MR by greater than 1 MR grade on serial
echocardiography are associated with left atrial and
ventricular dilatation and an overall poor prognosis [14].
Earlysurgeryisassociatedwithimprovedclinicaloutcome
in patients with severe asymptomatic MR [30]. This fact is
valid only when the regurgitation is carefully quantitated
and confirmed to be severe. This practice of operating on
asymptomatic MR should not be recommended based
upon the visual qualitative assessment of MR severity.
Color Doppler is notoriously poor at identifying the
population of asymptomatic patients who would
improve with valve surgery. In asymptomatic patients
withorganicMR,annualizedrateofchangeoftheeffective
regurgitant orifice area is strongly associated with
progression of symptoms and LV dysfunction [31].
Recent advances in the 3D matrix-array TEE technology
have improved the assessment of native MV compo-
nents, and this technology has become a valuable tool in
the assessment of prosthetic valves, particularly mitral
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prognostic assessment of both native and prosthetic MVs
before surgery but also serves as a superior means of
postoperative evaluation.
Three-dimensional echocardiography, either transthor-
acic or TEE, is useful in planning for MV repair and will
certainly play a crucial role in the percutaneous
treatment of MV disease [20]. Moreover, given the
improved quantitation of LV and RV volumes, the role
of 3DE in expanding our knowledge of patient outcomes
will continue to improve. Since the major consequence
of valvular heart disease is not the valve per se but the
myocardium, which remains in jeopardy of failing if the
valve disease is left unrepaired too long, careful
measurement of serial myocardial volumes will be
crucial. This fact has been recently highlighted with
pulmonary regurgitation. An aggressive surgical inter-
vention policy that intervenes with pulmonary valve
replacement prior to a right ventricular end-systolic
volume of greater than 150 mL/m
2 will result in a
normalization of volumes as well as improvement in
both biventricular systolic function and exercise capacity
[33]. Through adherence to this quantitative prognostic
concept, it is hoped that RV dysfunction will be less
common and in time patient outcomes for this valve
disease will show improvement.
Valvular heart disease is a well-known cause of left
ventricular dysfunction and heart failure symptoms.
Measurements obtained via TDI can be used in the
classification and prognosis of patients with LV dysfunc-
tion [34]. The E/E
0 ratio predicts functional class in
patients with heart failure (class IV = 12.9 ± 2.8 versus
class III = 8.3 ± 1.7) [34]. This simple measure, routinely
performed during all echo exams, holds true for patients
with MR, in whom the E/E
0 ratio predicts all-cause
mortality and worsening heart failure [17]. This value
should be used clinically as a guide to increase afterload-
reducing agents or diuretic therapy or both if the E/E
0
ratio exceeds 15-20.
Conclusions
Given our greater understanding of the prognostic
implications of these readily obtained echocardiographic
variables, this diagnostic tool will remain the primary
workhorse for the evaluation of patients with valvular
heart disease. Use of these variables may indicate the
need for early surgery for some patients with valvular
heart disease. Echo should be considered at least partly
responsible for the significant reductions in morbidity
and mortality that have recently been demonstrated in
patients with valvular heart disease. Physicians with
expertise in this field should expand their evaluation
beyond the basic structural and functional interpretation
to a more clinically valuable prognostic report, taking the
findings summarized in Table 1 into consideration.
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